Summit Therapeutics (NASDAQ: SMMT) is one of those stocks that have been quite explosive: The share price of the ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis ...

Combined company expected to trade on Nasdaq under “KLRS” after closingPALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 ...

Summit Therapeutics (SMMT) stock gains as Cantor Fitzgerald issues an Overweight rating highlighting the company's lead asset ...

Anti-VEGF not only inhibits angiogenesis but also ... which leads to enhanced efficacy of anti-PD-(L)1 inhibitors. Combining anti-PD-(L)1 antibodies with antiangiogenic agents was found to have ...

PSMA may be a noninvasive biomarker for predicting treatment response in metastatic clear cell renal cell carcinoma (RCC).

CTX-10726 is designed to synergistically deliver VEGF-A blockade and checkpoint inhibition, potentially applicable to multiple solid tumor indications. The bispecific antibody demonstrates a highly ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...